Drug Trial Radar · NCT00034372
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
Last checked: Nov 19, 2026Latest source record: Dec 18, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
102
Actual
Start
Sep 2000
Primary completion
Not stated
Study completion Dec 2007
Sponsor
- Lead sponsor
- Unither PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2002
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, patients will be randomized to one of three dose regimen groups. Each dose of OvaRex MAb-B43.13 is 2 mg by slow intravenous administration. Group 1 will receive two doses, one month apart. Group 2 will receive three consecutive monthly doses, then at 12-week intervals through 2 years or until disease relapse up to a total of 9 doses. Group 3 will receive six consecutive monthly doses, then at 12-week intervals through 2 years or until disease relapse up to a total of 11 doses. The study will compare the time to disease relapse of patients who demonstrate an immune response to OvaRex MAb-B43.13 with time to disease relapse of those who do not demonstrate an immune response to OvaRex MAb-B43.13. Differences in the percentage of patients demonstrating an immune response in each dose regimen group will also be assessed.
Conditions
- Ovarian Neoplasms
Interventions
oregovomabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Gynecologic Oncology Associates
Newport Beach, California
Stanford University Medical Center
Stanford, California
Walt Disney Memorial Cancer Institute
Orlando, Florida
St. Joseph's Regional Medical Center
South Bend, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Parker Hill Oncology & Hematology
Boston, Massachusetts
Ellis Fischel Cancer Center
Columbia, Missouri
Roswell Park Cancer Institute
Buffalo, New York
Baptist Hospital of East Tennessee
Knoxville, Tennessee
Texas Oncology, P.A.
Dallas, Texas
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
Swedish Medical Center Tumor Institute
Seattle, Washington
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cancer Care Manitoba
Winnipeg, Manitoba, Canada
Ottawa Regional Cancer Centre
Ottawa, Ontario, Canada
Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont
Fleurimont, Quebec, Canada
SMBD Jewish General Hospital
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.